Efficacy and safety of cladribine in treatment of patients with refractory/relapsed acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2016.12.009
- VernacularTitle:克拉屈滨治疗难治复发急性髓系白血病效果与安全性分析
- Author:
Lijuan RU
;
Hai LIN
;
Yehui TAN
;
Yanping YANG
;
Shanshan LIU
;
Xiangui LIU
;
Wenjing LIU
;
Sujun GAO
- Keywords:
Leukemia,myeloid,acute;
Cladribine;
Recurrence;
Refractory
- From:
Journal of Leukemia & Lymphoma
2016;25(12):739-742
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of cladribine in the treatment of patients with refractory/relapsed acute myeloid leukemia (AML). Methods The data of 8 patients with refractory/relapsed AML treated with regimens containing cladribine at a dose of 5 mg/m2 per day for 5 consecutive days were retrospectively analyzed. The efficacy and adverse reactions were observed during treatment. Results Among the 8 patients, 5 patients achieved complete remission (CR), 1 patient achieved partial response (PR), and 2 patients obtained non remission (NR). The adverse reactions could be tolerated. Conclusion Regimen containing cladribine is an effective treatment procedure for the patients with refractory/relapsed AML, and its adverse reactions can be tolerated, which requires further clinical study.
